
CAS 115103-85-0
:Formel:C26H26ClN2NaO3S2
InChl:InChI=1S/C26H27ClN2O3S2.Na/c1-29(2)24(30)12-14-33-26(34-15-13-25(31)32)20-5-3-4-18(16-20)6-10-22-11-8-19-7-9-21(27)17-23(19)28-22;/h3-11,16-17,26H,12-15H2,1-2H3,(H,31,32);/q;+1/p-1/b10-6+;
InChI Key:XNAYQOBPAXEYLI-AAGWESIMSA-M
SMILES:CN(C)C(=O)CCSC(C1=CC=CC(=C1)/C=C/C2=NC3=C(C=CC(=C3)Cl)C=C2)SCCC(=O)[O-].[Na+]
Filtern nach
Reinheitsanteil
0
100
|
0
|
50
|
90
|
95
|
100
6 Produkte gefunden.
- Niedrigster Preis
- Höchster Preis
- Niedrigste Reinheit
- Höchste Reinheit
- Schnellste Lieferung
MK-571 sodium
CAS:MK-571 sodiumFormel:C26H27ClN2O3S2·NaReinheit:99.5%Farbe und Form:SolidMolekulargewicht:537.07Propanoic acid, 3-[[[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl][[3-(dimethylamino)-3-oxopropyl]thio]methyl]thio]-, sodium salt, (E)- (9CI)
CAS:Formel:C26H26ClN2NaO3S2Reinheit:95%Farbe und Form:SolidMolekulargewicht:537.0690Sodium (E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoate
CAS:Sodium (E)-3-(((3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)((3-(dimethylamino)-3-oxopropyl)thio)methyl)thio)propanoateFormel:C26H26ClN2NaO3S2Reinheit:95%Molekulargewicht:537.07MK-571 sodium salt
CAS:Formel:C26H26ClN2O3S2·NaReinheit:≥ 97%Farbe und Form:White to light yellow or beige solidMolekulargewicht:537.1MK-571 sodium
CAS:MK-571 sodium, a CysLT1 antagonist and MRP2 inhibitor, obstructs drug efflux and hampers enterocyte phase-2 conjugation of flavonoids.Formel:C26H26ClN2NaO3S2Reinheit:97.86% - 99.58%Farbe und Form:SolidMolekulargewicht:537.069MK-571 sodium
CAS:MK-571 is a drug that belongs to the class of ATP-binding cassette transporters. MK-571 has been shown to inhibit multidrug efflux pumps, such as P-glycoprotein (P-gp), and to bind DNA. The optimum concentration of this drug is 0.1 μM, which can be achieved by using MK-571 with nonsteroidal anti-inflammatory drugs (NSAIDs). This agent has been shown to have a protective effect on the myocardium following a myocardial infarct and may also have an inhibitory effect on leukotriene synthesis in bowel disease. MK-571 has also been shown to inhibit polymerase chain reactions and may act as an inhibitor of apical secretions in the gastrointestinal tract.Formel:C26H27ClN2NaO3S2Reinheit:Min. 95%Molekulargewicht:538.08 g/mol





